



## Axovant Announces First Parkinson's Disease Gene Therapy R&D Day and Participation in Upcoming September Conferences"

September 8, 2020

*- Parkinson's Disease R&D Day to be hosted by Gavin Corcoran, MD, Chief R&D Officer, on October 30<sup>th</sup>, 2020, with leading movement disorder specialists*

NEW YORK and BASEL, Switzerland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that the company will provide a corporate overview and participate in 1:1 meetings at upcoming virtual investor and patient conferences in September. Additionally, the company announced plans for their 1<sup>st</sup> Parkinson's Disease R&D Day with key opinion leaders.

Investor and Patient Conference Presentation details:

### *Baird Global Healthcare Conference*

Date: Wednesday, September 9, 2020  
Time: 9:40 AM ET

### *2020 Virtual GM1 Family Meeting*

Date: Thursday, September 10, 2020  
Time: 6:45 PM ET

Registration Link: <https://curegm1.org/2020-gm1-family-meeting-san-francisco/>

### *Cantor Fitzgerald Virtual Global Healthcare Conference*

Date: Thursday, September 17, 2020  
Time: 1:20 PM ET

Webcast link: <https://www.webcaster4.com/Webcast/Page/2495/37417>

### *20<sup>th</sup> Annual Biotech in Europe Forum*

Date: Thursday, September 24, 2020  
Time: 9:00 AM ET

Registration link: <https://www.sachsforum.com/20bef-registration.html>

### *AXO-Lenti-PD Parkinson's Disease R&D Day*

Date: Friday, October 30, 2020  
Moderator: Gavin Corcoran, MD, Chief R&D Officer, Axovant Gene Therapies  
Additional details to be provided later in September.

A live webcast of the presentations will be available in the Events section of Axovant's website at [www.axovant.com](http://www.axovant.com). A replay will be available for approximately 30 days following the conference.

### **About Axovant Gene Therapies**

Axovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates target GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinson's disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit [www.axovant.com](http://www.axovant.com).

### **Contacts:**

#### **Media & Investors**

Parag Meswani  
Axovant Gene Therapies Ltd.  
(212) 547-2523  
[media@axovant.com](mailto:media@axovant.com)  
[investors@axovant.com](mailto:investors@axovant.com)

Source: Axovant Gene Therapies

